Novartis says court battle will delay its Enbrel copy until 2018 at least
January 25, 2017 at 07:39 AM EST
ZURICH, Jan 25 (Reuters) - The Novartis copy of Amgen's blockbuster psoriasis drug Enbrel will not go on sale before 2018 at the earliest because of the U.S. company's patent protection challenge, the Swiss drugmaker's head of generics told Reuters.
